Core Viewpoint - Aquestive Therapeutics received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application for Anaphylm, indicating deficiencies primarily related to human factors and labeling [1][2]. Group 1: FDA Response and Concerns - The FDA's CRL highlighted issues with the human factors validation study, including difficulties in opening the pouch and incorrect film placement, which could pose safety risks during anaphylaxis [2][3]. - The FDA's concerns are limited to human factors and a supportive pharmacokinetics (PK) study, with no additional studies requested [5]. Group 2: Company Actions and Future Plans - To address the FDA's concerns, the company has modified the pouch opening and labeling, and plans to conduct a new human factors validation study [4]. - The company estimates resubmission of the NDA in early Q3 2026, contingent on completing the necessary studies and typical FDA response times [6]. - Additionally, the company plans to submit a marketing authorization application in Europe and a New Drug Submission in Canada in the second half of 2026 [7]. Group 3: Market Reaction and Analyst Expectations - Following the news, Aquestive Therapeutics shares increased by 45.25% to $4.28 [8]. - Analyst expectations suggest that Anaphylm's approval decision may occur in the first half of 2027 [8].

1 These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with our development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials and plans for Anaphylm; risk of del ...

Core Viewpoint - Aquestive Therapeutics Inc. is experiencing a decline in stock price due to identified deficiencies in the New Drug Application for Anaphylm, which is a polymer matrix-based epinephrine prodrug product candidate aimed at treating severe allergic reactions, including anaphylaxis [2][3][6] Group 1: Stock Performance - The stock of Aquestive Therapeutics is trading lower, with a session volume of 5.68 million compared to the average volume of 2.79 million [1] - At the time of publication, shares were down 40.18% at $3.71 [6] Group 2: FDA Review and Deficiencies - The FDA has identified deficiencies in Anaphylm's New Drug Application that prevent discussions on labeling and post-marketing commitments [2] - The specific deficiencies have not been disclosed, but the company is actively working to understand and resolve these concerns [2][4] - The FDA's review of the application remains ongoing, and a Discipline Review Letter will not be issued, although information requests may occur during the review period [4] Group 3: Product Details and Future Plans - Anaphylm is designed to be a sublingual film that is similar in size to a postage stamp and begins to dissolve on contact, requiring no water or swallowing for administration [3] - The company plans to submit for regulatory approval of Anaphylm in Canada, Europe, and the U.K. by 2026 [3] Group 4: Financial Position and Future Outlook - As of the end of 2025, the company had approximately $120 million in cash and cash equivalents, which is believed to be sufficient for completing the Anaphylm approval and launch processes in the U.S. if approved [5] - Delays in communicating specific deficiencies may lead to further delays in the potential approval of Anaphylm [5]

Anaphylm (dibutepinephrine) Sublingual Film - The FDA confirmed that it will not require an Advisory Committee to review the Company's New Drug Application for Anaphylm[8] - The company is preparing for a U S launch in Q1 2026, if approved by the FDA[8] - The company broadened the patent estate for Anaphylm with the issuance of two new patents, extending patent protection into 2037[8] AQST-108 and AdrenaVerse Platform - The company plans to open Investigational New Drug application for AQST-108 with FDA in Q4 2025[11] - The company expects to initiate a clinical study for AQST-108 for Alopecia Areata in 1H 2026[11] Financial Position - The company successfully completed an equity raise of $85 million in August 2025[11] - The company also completed a strategic financing for $75 million with RTW Investments, LP, subject to FDA approval of Anaphylm and refinancing of the Company's existing debt[11] - The company's ending cash balance in Q3 2025 was $129.1 million[17] - The company expects to meet near-term milestones with projected cash runway into 2027[16] - The company's 2025 outlook includes total revenues of approximately $44-$50 million and a non-GAAP adjusted EBITDA loss of approximately $47-$51 million[23]

Group 1 - U.S. stocks experienced an upward trend, with the Nasdaq Composite increasing by over 100 points on Friday [1] - CoreWeave, Inc. (CRWV) saw a significant rise in shares, jumping 4.8% to $127.15 after Loop Capital initiated coverage with a Buy rating and set a price target of $165 [1] - Quantum Computing Inc. (QUBT) shares surged by 22.5% to $22.47, indicating strong market interest [3] Group 2 - WhiteFiber, Inc. (WYFI) gained 17.6% to $27.53, with Roth Capital analyst maintaining a Buy rating and raising the price target from $25 to $28 [3] - Serve Robotics Inc. (SERV) rose 17% to $15.09, reflecting positive investor sentiment [3] - Aquestive Therapeutics, Inc. (AQST) increased by 16.5% to $5.75 after receiving news from the FDA that an advisory committee meeting is not required for its product [3] Group 3 - PureTech Health plc (PRTC) gained 16.2% to $17.08, showing strong performance in the market [3] - NANO Nuclear Energy Inc. (NNE) rose 15.3% to $44.10, indicating robust investor confidence [3] - Newegg Commerce, Inc. (NEGG) jumped 15% to $53.51, reflecting a positive market reaction [3] Group 4 - Oklo Inc. (OKLO) gained 14.4% to $120.13, continuing a remarkable 60% rally over the past month [3] - NuScale Power Corporation (SMR) rose 12.6% to $42.99, indicating strong market interest [3] - Centrus Energy Corp. (LEU) gained 9.4% to $287.38, reflecting positive investor sentiment [3] Group 5 - Symbotic Inc. (SYM) shares rose 8.5% to $55.59, indicating strong market performance [3] - Rigetti Computing, Inc. (RGTI) gained 8.5% to $26.98 after being awarded a three-year $5.8 million contract from the Air Force Research Laboratory [3] - Barrick Mining Corporation (B) rose 7% to $32.17, with B of A Securities analyst maintaining a Neutral rating and raising the price target from $29 to $34 [3] Group 6 - FedEx Corporation (FDX) gained 2.4% to $231.98 after reporting better-than-expected first-quarter EPS and sales, leading multiple analysts to raise their price targets [3]

Core Viewpoint - The FDA has informed Aquestive Therapeutics that no advisory committee meeting is required for the NDA of Anaphylm, indicating the target action date remains January 31, 2026 [1][5][7]. Company Developments - Shares of Aquestive Therapeutics rose by 28.1% following the FDA announcement [2][7]. - The stock has increased by 42.2% year-to-date, outperforming the industry average increase of 11.7% [4]. - The NDA for Anaphylm was accepted by the FDA in June 2025, with the target action date set for January 31, 2026 [5][7]. - Anaphylm is being developed as a non-invasive oral epinephrine product for treating severe allergic reactions, including anaphylaxis [6][8]. Market Potential - If approved, Anaphylm would be the first non-invasive, orally delivered epinephrine product approved by the FDA for severe allergic reactions [6][8]. - The management believes Anaphylm offers greater convenience compared to traditional autoinjectors [7]. - The company has secured $160 million in financing to support the potential launch of Anaphylm in the U.S. in Q1 2026 [8].